Gene Therapy Breakthrough: MIT Engineers Develop Precise Control over Gene Expression

MIT engineers have successfully developed a control circuit that can keep expression levels within a target range, making it a significant breakthrough in the field of gene therapy. This innovation has the potential to treat a wide range of diseases by delivering genes that can help repair or replace faulty genes. The new approach uses a type of circuit called an incoherent feedforward loop (IFFL), which can be designed to express the correct amount of the therapeutic gene, eliminating the risk of underexpression or overexpression. The MIT team, led by Katie Galloway and Kasey Love, demonstrated the effectiveness of this system by delivering genes that could help treat diseases such as Fragile X syndrome, Friedreich's ataxia, and Rett syndrome.

Key Takeaways:

• The MIT team developed a control circuit that can keep expression levels within a target range, a significant breakthrough in the field of gene therapy.
• The circuit uses an incoherent feedforward loop (IFFL), which can be designed to express the correct amount of the therapeutic gene, eliminating the risk of underexpression or overexpression.
• The approach was demonstrated in human cells and showed that gene expression levels could be tuned to about eight times the normal level.
• Without the control circuit, gene expression was more than 50 times the normal level, which could pose safety risks.
• The researchers plan to study whether this approach can be used to deliver genes at a level that would restore normal function and reverse signs of disease in cultured cells or animal models.
• The control circuit's compact design allows it to be carried on a single delivery vehicle, such as a lentivirus or adeno-associated virus, which could improve the manufacturability of these therapies.
• The researchers also performed tests in rat neurons, mouse fibroblasts, and human T-cells, with similar results.

Statistics:

• Gene expression levels could be tuned to about eight times the normal level, a significant improvement over the previous 50 times the normal level without the control circuit.
• The researchers plan to study whether this approach can be used to deliver genes at a level that would restore normal function and reverse signs of disease in cultured cells or animal models.
• The control circuit's compact design allows it to be carried on a single delivery vehicle, such as a lentivirus or adeno-associated virus, which could improve the manufacturability of these therapies.

Sources:

• Paper: "Compact microRNA-mediated attenuator of noise and dosage (ComMAND) for gene therapy" by Kasey Love, et al. in Cell Systems.
• Study conducted at the Massachusetts Institute of Technology (MIT) under the direction of Katie Galloway and Kasey Love.
• Published in Cell Systems on May 18, 2025.